Please login to the form below

Not currently logged in


This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

Bayer's lymphoma drug copanlisib gets speedy FDA review

Bayer's lymphoma drug copanlisib gets speedy FDA review

Bayer is in pursuit of Gilead Sciences' P13K inhibitor Zydelig (idelalisib), which is already approved for FL and chronic lymphocytic leukaemia (CLL) in the US but hasn't lived up to ... It's worth noting that idelalisib targets a single P13K isoform

Latest news

More from news
Approximately 4 fully matching, plus 27 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company

Our higher purpose is to deliver better communication to increase and speed up the ability of patients to access better...

Latest intelligence

social media
Engaging the digital healthcare professional
How to plan relevant customer strategies in the digital age...
Launching the next big thing in vascular intervention
A case study by Create Health...
content marketing
Are patients ready for digital doctors?
How can technology truly benefit health delivery?...